CMS

  • Medicare Drug Claims Met a Code Check With No Guard at the Door

    Medicare claims can encounter many checks on their way through the system. One relevant check, it turns out, was missing: a system edit to verify that the procedure code billed alongside a drug matched the codes associated with that drug in CMS crosswalk files. The HHS Office of Inspector General has now put that gap on paper, where it sits with the stillness of a form that knows it has been noticed.

    OIG reviewed Medicare Part B outpatient drug claims from April 1, 2024, through March 31, 2025. It identified 160,918 claim lines with procedure-code and drug-code mismatches when compared with the CMS crosswalk files. A mismatch is a flag for review, not proof that a provider used the wrong code or that Medicare paid incorrectly. The crosswalk is a reference; the finding says the codes did not line up with it.

    Medicare paid $27.6 million for those claim lines. That figure needs its own guardrail: OIG did not determine whether the mismatches caused overpayments or underpayments across the 160,918 lines. So this is not a report establishing $27.6 million in losses, recoverable money, or improper payments. It is the amount paid on claims that met the report’s mismatch criteria. The number is large; the conclusion is narrower.

    OIG also examined a nonstatistical sample of 30 claim lines. In that sample, it found incorrect procedure codes on 24 lines. Eleven of those 24 were paid under a system in which the errors could have resulted in improper payments. Those are sample findings, not a projection about all 160,918 lines. The sample shows why the mismatch deserved scrutiny; it does not calculate the overall financial effect.

    The report identifies two control weaknesses. CMS and its contractors lacked system edits to check the relevant code matches, and provider education did not specifically address those mismatches. In bureaucratic terms, the paperwork could identify a pairing worth checking, but the routine gate did not perform that check—and the guidance did not put the issue plainly in front of providers. The filing coughed; the controls remained seated.

    For patients and taxpayers, the useful takeaway is not that every flagged claim was wrong. It is that a national oversight system had an identified code-matching risk without a specific automated check or targeted education, while the report could not establish the payment impact across the full set. That distinction matters. Accountability begins with finding the missing check, then measuring what it actually allowed through—not turning a flagged total into a verdict the audit did not reach.

  • |

    CMS’s Proposed PBM Rule Puts Payment Details on the Table

    CMS proposed new Medicare Part D rules on October 16 aimed at making pharmacy benefit managers (PBMs) explain more of their compensation and contractual arrangements. The proposal raises a useful invoice question: who pays the PBM, and what service is that payment buying? In health care, the answer can arrive dressed as a spreadsheet wearing a fake mustache.

    More detail for plan sponsors

    Under the proposal, PBMs would provide annual reporting on their compensation and cost performance in Part D. CMS also proposes greater transparency around price guarantees and disclosure to plan sponsors of certain terms in agreements between PBMs and drug manufacturers. Those details could help sponsors assess what they are paying for and how the arrangement is performing.

    That information would not automatically become public. The proposal focuses on reporting and disclosures for plan sponsors, giving them more material to examine; it is not a promise that every contract term or payment detail will be posted for everyone to see. More paperwork in the hands of the people managing a plan may improve their ability to scrutinize an arrangement, but it does not guarantee what they will conclude or do with it.

    The proposal also addresses how PBMs are compensated, with limits tying certain compensation to the fair market value of services rather than to drug costs. The distinction matters: a fee linked to a drug’s price can create a different incentive from a fee tied to a defined service. CMS’s proposal aims to make the relationship easier to inspect. Its practical effect would depend on the final requirements and how plan sponsors use the information.

    Transparency is not a discount coupon

    CMS says the proposal implements provisions in the 2026 Consolidated Appropriations Act. The agency’s fact sheet describes reporting, price-guarantee transparency, manufacturer-agreement disclosures and compliance requirements. But a proposal is not a receipt showing that a patient’s next prescription will cost less. The proposed disclosures do not establish that premiums or out-of-pocket costs will fall. Better information may help plan sponsors evaluate contracts; whether that changes what patients pay remains an open question.

    That is the useful distinction for patients and taxpayers: the policy is aimed at making payment arrangements easier for plan sponsors to examine, not announcing a price cut. A sponsor getting a clearer view of compensation and contract terms is a step toward accountability. It is not the same as savings reaching the pharmacy counter. Follow the invoice, then check whether the benefit made it past the conference room.

    Still a proposal

    The Federal Register inspection copy schedules publication for October 20, 2026, and lists December 15, 2026, as the deadline for comments. The rule is proposed, not final or already in effect. For now, CMS has put additional PBM payment and contract information on the table for plan sponsors to examine. The next test is whether clearer paperwork produces better oversight—and whether any gains eventually reach the people paying for prescriptions.

  • |

    The Drug Pricing Rule Has a Lobbyist in the Back Seat

    I look at Washington’s healthcare paperwork the way a diner waitress looks at a fake coupon: polite, tired, and already hunting for the fine print. CMS is considering a proposed Medicare rule that could treat certain fixed-combination drugs as the same qualifying single-source drug as an originator medicine for price negotiation. Patients may see one prescription. The policy question is whether Washington sees one product—or several convenient identities parked under the same hood.

    CMS issued the proposal June 12, set an August 17 comment deadline, and is expected to finalize it in fall 2026. That makes this less a chemistry quiz than a money-trail dispute. If a combination product remains legally separate from the medicine it combines, more revenue could remain outside the negotiation process. That is not proof anyone designed the product as an escape hatch. It is the practical question sitting on the counter while everyone argues about labels.

    Inside Health Policy reported that biologics manufacturers objected to CMS’s approach, arguing that separate FDA categories raise legal-authority and innovation concerns. Those are serious arguments, and agencies should not smuggle major policy changes through a filing cabinet labeled “technical clarification.” But the industry’s preferred separation also has a financial consequence: separate categories can mean separate treatment when Medicare decides what qualifies for negotiation.

    This is where the fine print starts wearing donor perfume. The public argument is about innovation, regulatory boundaries, and whether CMS has gone too far. The money question is simpler: who benefits if the category stays split? Manufacturers may preserve separate revenue streams from negotiated pricing, while patients and taxpayers are left to admire the elegance of the classification system from the payment window.

    At the pharmacy drive-through, nobody orders “one originator medicine with a regulatory garnish.” They get a prescription. In Washington, however, one prescription can be asked to produce two billing identities, two receipts, and two opportunities to keep the negotiated-price window closed. The rule is still proposed, the dispute is still active, and the invoice has not finished crawling out from under the lobbyist’s coat. But the public should know what this technical fight can decide: whether a medicine’s category serves patients—or protects the revenue attached to it.

    Sources

  • |

    When Efficiency Locks the Front Door

    I ran the arithmetic on the Biden-Harris plan to expand home-based care versus the Trump policy freeze described around CMS, and the numbers have a familiar county-office quality: fewer new providers may look tidy on paper, but a locked door is not an appointment. Supporting family caregivers, improving care jobs, and helping seniors remain independent all require actual capacity—not merely a promise that capacity would be nice.

    Fraud prevention matters. So does not confusing “fewer entrants” with “better access.” If legitimate home-health agencies and hospice providers cannot get through the front door, seniors wait, families absorb another unpaid shift, and care workers are asked to perform fiscal miracles before lunch. The spreadsheet may show fewer bad actors. It also shows a locked door, and the person outside still needs a caregiver.

  • |

    Seniors Need Care at Home—Not a Nationwide Freeze: Existing Providers Stay, New Providers Stop

    “Help seniors stay at home” gets a choir seat on the Biden-Harris side: expand home & community care, support caregivers, strengthen care-worker pay. Then the Trump CMS side clears its throat with the paperwork plan: a 6-month nationwide freeze, new home health enrollments blocked, new hospice enrollments blocked—while the banner insists on the comforting contradiction: existing providers stay. New providers stop.

    Here’s the moral audit: bureaucracy calls it compassion because seniors can “stay at home.” Families hear the real deal—no new providers means the waiting room migrates into the living room. Mercy delayed by forms is still mercy delayed, and somebody always gets to repeat the slogan while other people run out of options.

  • |

    The Stroke Code That Needed A Receipt

    The document coughed, and out came the familiar Medicare Advantage ghost story: CMS auditors looking at an HHS-OIG oversight item found overpayment concerns tied to serious diagnosis codes that were not supported by the medical records. Not patients. Not bedside judgment. The target here is the risk-coding machine, where a diagnosis can enter the payment bloodstream with federal seriousness, then become shy when someone asks where it lives in the folder.

    This is the bureaucracy’s finest magic trick: crisp enough to affect payment, foggy enough to need a lantern. In public-records terms, if a diagnosis code is sturdy enough to help bill the government, it should be sturdy enough to stand upright when the file drawer opens. Otherwise, we are not doing health oversight. We are conducting a séance for a receipt.

  • |

    When a Virtual Check‑In Feels Like a Paperwork Excuse: OIG Unearths $2.26 Million in Sketchy Remote Visits

    In an April 23, 2026 audit from the Office of Inspector General (OIG), a long-hidden bureaucratic gem emerged—approximately $2.26 million in potentially improper Medicare payments for virtual check-ins and e-visits. Reading like the diary nobody locked, this audit finds that something was amiss in the virtual halls of healthcare billing.

    This isn’t just about imaginary band-aids on imagined cuts. It’s about weaknesses in oversight that allowed these virtual care payments to balloon into multimillion-dollar windfalls, all while CMS was haunted by gaps in system edits and provider education. The very nature of paperwork itself stands accused of duplicity.

    The OIG report breaks it down: around $1.96 million tied to virtual check-ins coincided suspiciously with recent or next-day Evaluation/Management visits. Meanwhile, duplicate billing during e-visits added another $298,200 to the tab. In total, 173,287 services went unnoticed under timelines tighter than a bureaucrat’s grip on their favorite pen.

    No, it’s not fraud; we’re talking ‘potentially improper’—a distinction as sharp and necessary as the label on a mystery envelope that says, ‘Do Not Open.’ The blame lies partly with missing system edits in CMS and the MACs, compounded by bewildered providers deciphering modifiers like an undecided jury.

    The Office of Inspector General, with the calm gravitas of a librarian discovering a hidden annex, offered a roadmap: implement system edits (which CMS accepted), fortify code descriptions (less enthusiasm there), and bolster provider education (agreed upon with the eagerness of a clerk discovering extra forms to file).

    So why should this matter? Because it’s taxpayer money squirming away through administrative fissures. The report’s findings underscore just how bizarrely captivating paperwork can be—we don’t always see the full story unless someone turns on the filing cabinet’s lamp.

    Remember: this isn’t just a tale of fiscal oversight missing a beat. It’s about the modifiers that walked in wearing suspiciously innocent labels, revealing a system that promises future improvements. Yet, even as edits loom, expect the receipts to keep sweating.

    Sources

End of content

End of content